Renalytix Plc (AIM: RENX)

Market Cap	16.18M
Revenue (ttm)	1.76M
Net Income (ttm)	-29.68M
Shares Out	165.93M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,100
Open	10.50
Previous Close	10.25
Day's Range	10.25 - 10.50
52-Week Range	10.00 - 103.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 27, 2024

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical tr...

• Industry: Medical - Healthcare Information Services
• Sector: Healthcare
• Founded: 2018
• Employees: 102
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: RENX

Financial Performance

In 2023, Renalytix's revenue was $3.40 million, an increase of 14.58% compared to the previous year's $2.97 million. Losses were -$45.61 million, 0.73% more than in 2022.

Financial numbers in USD